Immune checkpoint inhibitor-bullous pemphigoid is characterized by interleukin-4 and interleukin-13 expression and responds to dupilumab treatment.
William D Shipman, Katelyn Singh, Jeffrey M Cohen, Jonathan Leventhal, William Damsky, Mary M TomaykoNo abstract text is available yet for this article.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.